SANOVO: 1L EGFR-mutant, MET-overexpressing advanced NSCLC. Savolitinib + osimertinib vs osimertinib: median PFS 24.9 vs 13.8 months (HR 0.56). Primary PFS met. Should MET testing m

Nurullah İlhan,MD· @drnurullahilhan · X·2026-10-26 20:24· 9 小时前评分70

正文 · 原文

SANOVO: 1L EGFR-mutant, MET-overexpressing advanced NSCLC. Savolitinib + osimertinib vs osimertinib: median PFS 24.9 vs 13.8 months (HR 0.56). Primary PFS met. Should MET testing move upfront? @OncoDaily @OncoAlert #ESMO26

3 浏览 · 0 赞 · 0 转发 · 0 回复

来源：Nurullah İlhan,MD · x.com